19 May 2014
On 16 May 2014, the Inland Revenue Authority of Singapore (“IRAS”) issued the e-Tax Guide “Pharmaceutical Manufacturing Industry: Tax Treatment of Research & Development and Intellectual Property-Related Expenditures (Second Edition)”.
The e-Tax guide provides guidance on tax treatments for the following items common to pharmaceutical manufacturing companies in:
(a) Deduction of research and development(“R&D”) expenditure under sec 14D and sec 14DA of the Income Tax Act (“the Act”);
(b) Writing down allowances under sec 19B of the Act;
(c) Provision of R&D services;
(d) Deduction of royalty payments and withholding tax implications.
The new edition reflects the changes to R&D since the first edition of the e-Tax Guide was published on 22 August 2011. The major changes are:
- The extension of the R&D scheme from year of assessment (“YA”) 2015 to YA 2025;
- The expansion of sec 14D and sec 14DA to include payments made under R&D cost-sharing agreements with effect from YA 2012; and
- The removal of writing down allowances claim under sec 19C for approved R&D cost sharing agreements.
For the full details, please refer the e-Tax Guide on the IRAS website.
Source: Inland Revenue Authority of Singapore
You must be logged in to post a comment.